A promising new study, released as a preprint on the bioRxiv* server, reports on the high neutralizing efficacy of a polyclonal swine antibody against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.
